FY2017 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Boosted by Analyst (ARWR)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Analysts at Cantor Fitzgerald increased their FY2017 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Wednesday. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will earn ($0.41) per share for the year, up from their previous forecast of ($0.48). Cantor Fitzgerald also issued estimates for Arrowhead Pharmaceuticals’ FY2018 earnings at ($0.43) EPS.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. The firm had revenue of $9.34 million during the quarter, compared to the consensus estimate of $5.29 million.
A number of other analysts have also recently commented on ARWR. ValuEngine cut shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Piper Jaffray Companies restated a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, July 28th. Finally, Jefferies Group LLC restated a “hold” rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, August 4th. One research analyst has rated the stock with a sell rating and five have given a hold rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $1.80.
Arrowhead Pharmaceuticals (ARWR) opened at 2.64 on Monday. The company has a 50-day moving average price of $1.82 and a 200 day moving average price of $1.79. The stock’s market capitalization is $197.40 million. Arrowhead Pharmaceuticals has a 1-year low of $1.20 and a 1-year high of $8.09.
Institutional investors have recently bought and sold shares of the company. Virtu KCG Holdings LLC raised its position in Arrowhead Pharmaceuticals by 115.6% in the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 53,215 shares in the last quarter. LMR Partners LLP bought a new position in Arrowhead Pharmaceuticals during the second quarter valued at about $467,000. Geode Capital Management LLC raised its position in Arrowhead Pharmaceuticals by 3.4% in the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock valued at $1,226,000 after buying an additional 21,654 shares in the last quarter. SG Americas Securities LLC raised its position in Arrowhead Pharmaceuticals by 287.9% in the first quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 74,776 shares in the last quarter. Finally, UBS Asset Management Americas Inc. raised its position in Arrowhead Pharmaceuticals by 414.7% in the first quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after buying an additional 53,500 shares in the last quarter. 20.63% of the stock is owned by hedge funds and other institutional investors.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Stock Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.